MONTREAL, May 13, 2019 /PRNewswire/ -- At the Annual
Meeting of the International Society for Magnetic Resonance in
Medicine (ISMRM), Bruker today announced an agreement to develop
the world's first 18 Tesla 11 cm bore, preclinical ultra-high field
(UHF) magnetic resonance imaging (MRI) system and its clinical
research applications in collaboration with the Champalimaud
Foundation. This novel and unique system is expected to enable
Champalimaud researchers to advance translational cancer and
neuroscience research with UHF MRI and magnetic resonance
spectroscopic imaging.
The 18T MRI is expected to be installed in late 2021 in the
Neuroplasticity and Neural Activity laboratory under Dr.
Noam Shemesh, with the goal to
develop novel contrast mechanisms in MRI and spectroscopic
imaging. The Champalimaud Foundation focuses its research on
neuroscience and oncology, and the 18T system will advance the
Foundation's in vivo research into cancer, metastasis and
pre-metastatic niches (PMNs) in multiple cancer models. It will
also advance research into brain plasticity and activity in normal
and neurodegenerative disease models.
The ultimate goal of the Champalimaud Foundation is to improve
clinical outcomes. The preclinical 18T MRI will facilitate the
discovery of new spatially-resolved contrast mechanisms for
elucidating biological function, and it will enhance temporal
resolution to access additional information on brain dynamics.
Dr. Noam Shemesh, Principal
Investigator at the Champalimaud Foundation, stated: "We are very
excited to explore the full potential of the 18T MRI system, and to
advance our understanding of biological mechanisms underlying
healthy and diseased conditions. We intend to harness the 18T
ultra-high field and enhanced sensitivity to facilitate
investigations into microstructure and metabolism dynamics in the
brain, as well as in cancer, highlighting MRI as a tool for
answering fundamental questions in biology, and not 'just' as a
powerful diagnostic tool. We have a well-established, long-lasting
collaboration with Bruker, and we are fully confident in the new
science that will emerge from this project."
Dr. Wulf-Ingo Jung, President of
Bruker's Preclinical Imaging division, added: "We are extremely
pleased to partner with the Champalimaud Foundation to collaborate
on unique, enabling research tools to advance scientific research
in both neuroscience and oncology. This exciting UHF MRI
partnership will be a demonstration of what can be achieved in
collaboration with a leading medical research institution."
About Champalimaud Foundation (Fundação
Champalimaud)
The Champalimaud Foundation in Lisbon,
Portugal, is a leader and promoter of knowledge, working to
develop innovative projects and find solutions to the pressing
health problems around the globe. Professor Noam Shemesh's future research using the 18
Tesla system hopes to answer existing biological questions, such as
the exploration of early biomarkers for cancer, whilst creating
profound new questions for the future.
For more information:
https://m.fchampalimaud.org/en/champalimaud-research/
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker's high-performance scientific instruments and
high-value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular research, in applied and pharma applications, in
microscopy and nanoanalysis, and in industrial applications, as
well as in cell biology, preclinical imaging, clinical phenomics
and proteomics research and clinical microbiology.
For more information: www.bruker.com/products/mr/preclinical-mri
or www.bruker.com/events/ismrm
Investor Contact:
Pam
Clark
Bruker Investor Relations
T: +1 (978) 663-3660, ext. 1479
E: Investor.Relations@bruker.com
Media Contact:
Thorsten
Thiel, Ph.D.
Bruker BioSpin VP of Group Marketing
T: +49 (721) 5161–6500
E: thorsten.thiel@bruker.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bruker-and-champalimaud-foundation-announce-collaboration-to-develop-novel-ultra-high-field-18-tesla-preclinical-mri-system-and-applications-300848686.html
SOURCE Bruker Corporation